“魔法子弹”威力尽显！中国多项研究证实，ADC药物重塑多种癌症治疗格局

Core Viewpoint - The article discusses the advancements in Antibody-drug conjugates (ADCs) in cancer treatment, highlighting their effectiveness over traditional chemotherapy and their potential in various cancer types [2][16]. Group 1: ADC in Non-Small Cell Lung Cancer (NSCLC) - A study published on December 16, 2025, indicates that ADCs outperform chemotherapy in EGFR-TKI resistant NSCLC, based on a Bayesian network meta-analysis involving 19 randomized controlled trials with 4,039 participants [5][6]. - The ADC Sac-TMT significantly improved progression-free survival (PFS) and overall survival (OS) compared to traditional chemotherapy and other treatment strategies [6][7]. - The study concludes that Sac-TMT, Dato-DXd, and bispecific antibody-based treatments are the most effective options for advanced NSCLC patients who have progressed after EGFR-TKI therapy, with manageable toxicity [7]. Group 2: ADC and PD-1 Inhibitors in Metastatic Urothelial Carcinoma (mUC) - A study published on November 29, 2025, evaluates the combination of the ADC Disitamab Vedotin with PD-1 inhibitors in mUC, showing promising results in a cohort of 63 patients [9][11]. - The treatment response rates included 19.0% achieving complete response (CR) and 52.4% achieving partial response (PR), with an overall response rate (ORR) of 71.4% and disease control rate (DCR) of 87.3% [11][12]. - The study concludes that this combination therapy demonstrates good efficacy and controllable safety as a first-line treatment for mUC patients [12]. Group 3: ADC in HER2-Positive and HER2-Low Advanced Breast Cancer - A study published on February 28, 2025, assesses the efficacy and safety of T-DXd in Chinese patients with HER2-positive and HER2-low advanced breast cancer, involving 61 participants [14][15]. - The results show a median PFS of 10.51 months for the HER2-low group and 10.18 months for the HER2-positive group, with ORR of 37.93% and 62.50% respectively [14][15]. - The study indicates that T-DXd may be an effective treatment option for advanced breast cancer patients regardless of HER2 expression levels, with manageable adverse reactions [15].